Actualités

Novo Nordisk has reported headline phase 3 results from the ZEUS trial of ziltivekimab in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The study met key biomarker endpoints but did not reduce major adverse cardiovascular events compared with placebo. The outcome affects Novo Nordisk’s cardiovascular pipeline focus and is expected to trigger a non cash impairment in the upcoming quarter. The ZEUS readout lands at a sensitive time for Novo...

U.S.-traded shares of Novo Nordisk are down more than 6% due to a sales shortfall for its new Wegovy weight-loss pill and a disappointing study outcome for a next-generation weight-loss drug. Overall, the company sees the potential for a full-year sales decline of up to 6%, better than its previous view that sales could drop up to 12%. Novo also disclosed that its experimental drug CagriSema failed to show comparable blood-sugar reduction to Eli Lilly’s tirzepatide in a new study of people with Type 2 diabetes.

The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.

The Danish drugmaker's Wegovy pill has exceeded 5 million prescriptions in the U.S. since launch, driving stronger-than-expected profit

Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.

The Danish drugmaker said annual sales and operating profit should fall less than it previously expected following a boost in the second quarter.

Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand.

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

One year since becoming Novo Nordisk’s chief executive, Mike Doustdar is betting on the “phenomenal” sales of its weight-loss pill, new drugs...

Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?

NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.

LLY is set to report Q2 results on Aug. 5, with GLP-1 drugs expected to drive growth as investors watch Foundayo's early sales.

Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO), arguing that the market's reaction to a failed heart drug trial looks somewhat overdone while flagging deeper concerns about pricing and competition in obesity. The Danish group announced that ziltevekimab, an anti-inflammatory...

IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a […]

Eli Lilly stock has delivered very strong gains over the past five years, yet the latest valuation checks send mixed signals, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a sizeable gap below the current price while the broader scorecard still leans expensive. Eli Lilly has returned about 357.2% over five years, which puts extra focus on whether the current price already reflects investors' optimism. The FDA's Breakthrough Therapy designation for olomorasib can...

Earnings continue to be the market's engine, and a series of results this week from Palantir, SpaceX, and AMD are set to rev up stocks again.

With American alcohol consumption near historic lows, Boston Beer Company is fighting an uphill battle.

The monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.

Investors who had hopes that Novo Nordisk (NVO) could succeed outside of weight-loss drugs were disappointed on Friday, July 31. The Danish drugmaker said its experimental heart drug Ziltivekimab failed the main goal of a large late-stage trial, and the stock fell fast. Novo has spent 2026 trying ...

Trial setback puts focus on Novo Nordisk stock Novo Nordisk (NYSE:NVO) is under fresh scrutiny after the ZEUS phase 3 trial for heart drug candidate ziltivekimab failed to reduce major adverse cardiovascular events versus placebo, prompting a share price drop. See our latest analysis for Novo Nordisk. The ZEUS result comes after a tougher start to the year for Novo Nordisk, with the share price down 10.14% year to date and the latest 1 day move falling 8.78%. However, the 90 day share price...

Novo Nordisk stock has slipped over the past year and is down 36.4% over three years, yet the valuation checks still lean supportive, which sets up a different picture from what the share price alone might suggest. Recent headlines around the ZEUS trial setback and legal action against Eli Lilly have sharpened the focus on whether the current price fairly reflects the risks and opportunities. The share price decline of 36.4% over three years points to a period where investors who bought...

The Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.

BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever.

With the stock near a 5-year low, is it worth a look?

Key takeawaysNovo Nordisk’s U. S.

Novo Nordisk stock is sinking on a disappointing Phase 3 clinical trial. Here’s how you should play NVO shares following the dip.

Novo Nordisk (NVO) shares tumbled Friday after the Danish pharmaceutical giant said a late-stage tri

The global market for obesity drugs is soaring, yet Lilly has a dominant market share.

Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different stories about which company holds the upper hand heading into a pivotal summer of reports and pricing resets.

European stock markets closed mixed in Friday trading with the Stoxx 600 easing 0.1%, Germany's DAX